Trends in overall mortality among US veterans with primary myelofibrosis
Số trang: 8
Loại file: pdf
Dung lượng: 1.08 MB
Lượt xem: 9
Lượt tải: 0
Xem trước 1 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Primary myelofibrosis [PMF] is a myeloproliferative neoplasm associated with reduced overall survival (OS). Management strategies for PMF have evolved over the last two decades, including approval of ruxolitinib as the first Janus kinase 1 (JAK1)/JAK2 inhibitor for patients with intermediate or high-risk myelofibrosis. This study assessed changes in mortality before and after ruxolitinib approval, independent of ruxolitinib treatment.
Nội dung trích xuất từ tài liệu:
Trends in overall mortality among US veterans with primary myelofibrosis
Nội dung trích xuất từ tài liệu:
Trends in overall mortality among US veterans with primary myelofibrosis
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Primary myelofibrosis Myeloproliferative neoplasm associated Overall survival JAK2 inhibitorGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 171 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 118 0 0 -
12 trang 93 0 0
-
19 trang 74 0 0
-
17 trang 64 0 0
-
9 trang 43 0 0
-
12 trang 38 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 37 0 0